Results 151 to 160 of about 2,808,349 (298)

Integrase Inhibitor Prodrugs: Approaches to Enhancing the Anti-HIV Activity of β-Diketo Acids

Molecules, 2015
HIV integrase, encoded at the 3′-end of the HIV pol gene, is essential for HIV replication. This enzyme catalyzes the incorporation of HIV DNA into human DNA, which represents the point of “no-return” in HIV infection.
V. Nair, Maurice O Okello
semanticscholar   +1 more source

Integrase inhibitor‐based treatment in clinical practice

Journal of the International AIDS Society, 2010
7‐11 November 2010, Tenth International Congress on Drug Therapy in HIV Infection, Glasgow ...
M Feasi, N Bobbio, R Piscopo, Giovanni Cassola, Giovanni Cenderello, Giovanni Penco   +5 more
openaire   +2 more sources

Dual cross‐sectional and longitudinal perspective on the continuum of HIV care to disentangle natural epidemic evolution from real progress, Belgium 2014–2022

HIV Medicine, Volume 26, Issue 7, Page 1034-1045, July 2025.
Abstract Introduction This study provides a comprehensive overview of HIV care by combining cross‐sectional and longitudinal continuum of care (CoC) analyses. Methods Using national surveillance data 2014–2022, a five‐stage cross‐sectional CoC was calculated among people living with HIV (incl.
D. Van Beckhoven, B. Serrien, R. Demeester, J. Van Praet, P. Messiaen, G. Darcis, S. Henrard, P. De Munter, A. Libois, J. Deblonde   +9 more
wiley   +1 more source

2-Mercaptobenzenesulphonamides as Novel Inhibitors of Human Immunodeficiency virus Type 1 Integrase and Replication [PDF]

, 1997
Nouri Neamati, Abhijit Mazumder, Sanjay Sunder, J. M. Owen, R.J. Schultz, Yves Pommier   +5 more
openalex   +1 more source

Antiretroviral therapy use, self‐reported adherence, and viral suppression among women living with HIV in Canada

HIV Medicine, Volume 26, Issue 7, Page 1060-1073, July 2025.
Abstract Background Traditionally, ≥95% adherence was recommended for viral suppression (VS). Newer antiretroviral therapy (ART) is now being increasingly prescribed and may be more forgiving of lower adherence. The lifelong nature of ART presents adherence challenges, particularly for women living with HIV. We aimed to describe ART use and examine the
Maysaloun Mokaddam, Nadine Kronfli, Nancy L. Sheehan, Araceli Gonzalez Reyes, Danièle Dubuc, Mona Loutfy, Angela Kaida, Alexandra de Pokomandy, on behalf of the CHIWOS research team, Rahma Abdul‐Noor, Aranka Anema, Jonathan Angel, Dada Mamvula Bakombo, Fatimatou Barry, Greta Bauer, Kerrigan Beaver, Marc Boucher, Isabelle Boucoiran, Jason Brophy, Lori Brotto, Ann N. Burchell, Claudette Cardinal, Allison Carter, Lynne Cioppa, Tracey Conway, José Côté, Jasmine Cotnam, Cori d'Ambrumenil, Janice Dayle, Erin Ding, Danièle Dubuc, Janice Duddy, Mylène Fernet, Annette Fraleigh, Peggy Frank, Brenda Gagnier, Marilou Gagnon, Jacqueline Gahagan, Claudine Gasingirwa, Nada Gataric, Rebecca Gormley, Saara Greene, Danielle Groleau, Charlotte Guerlotté, Trevor Hart, Catherine Hankins, Emily Heer, Robert S. Hogg, Terry Howard, Shazia Islam, Joseph Jean‐Gilles, Hermione Jefferis, Evin Jones, Charu Kaushic, Mina Kazemi, Mary Kestler, Maxime Kiboyogo, Marina Klein, Nadine Kronfli, Gladys Kwaramba, Gary Lacasse, Ashley Lacombe‐Duncan, Melanie Lee, Rebecca Lee, Jenny Li, Viviane Lima, Elisa Lloyd‐Smith, Carmen Logie, Evelyn Maan, Valérie Martel‐Lafrenière, Carrie Martin, Renee Masching, Lyne Massie, Melissa Medjuck, Brigitte Ménard, Cari L. Miller, Judy Mitchell, Gerardo Mondragon, Deborah Money, Ken Monteith, Marvelous Muchenje, Florida Mukandamutsa, Mary Ndung'u, Valerie Nicholson, Kelly O'Brien, Nadia O'Brien, Gina Ogilvie, Susanna Ogunnaike‐Cooke, Joanne Otis, Rebeccah Parry, Sophie Patterson, Angela Paul, Doris Peltier, Neora Pick, Alie Pierre, Jeff Powis, Karène Proulx‐Boucher, Corinna Quan, Jesleen Rana, Eric Roth, Danielle Rouleau, Geneviève Rouleau, Sergio Rueda, Kate Salters, Margarite Sanchez, Roger Sandre, Jacquie Sas, Édénia Savoie, Paul Sereda, Stephanie Smith, Marcie Summers, Wangari Tharao, Christina Tom, Cécile Tremblay, Jason Trigg, Sylvie Trottier, Angela Underhill, Anne Wagner, Sharon Walmsley, Clara Wang, Kath Webster, Wendy Wobeser, Denise Wozniak, Mark H. Yudin, Wendy Zhang, Julia Zhu   +125 more
wiley   +1 more source

Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS

HIV/AIDS: Research and Palliative Care, 2014
Krishan K PandeyInstitute for Molecular Virology, Saint Louis University Health Sciences Center, St Louis, MO, USAAbstract: Human immunodeficiency virus type 1 (HIV-1) integrase inhibitors belong to a novel class of antiretroviral drugs with high potency
Pandey KK
doaj  

HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase [PDF]

, 2000
Amy S. Espeseth, Peter J. Felock, Abigail Wolfe, Marc Witmer, Jay A. Grobler, Neville J. Anthony, Melissa S. Egbertson, Jeffrey Y. Melamed, Steve Young, Terence G. Hamill, James L. Cole, Daria J. Hazuda   +11 more
openalex   +1 more source

Weight gain, obesity, and the impact of lifestyle factors among people living with HIV: A systematic review

Obesity Reviews, Volume 26, Issue 7, July 2025.
Summary HIV remains a significant health concern, but the advent of antiretroviral therapy (ART) has transformed it into a manageable chronic condition. However, weight gain and obesity pose a substantial challenge for people living with HIV (PLWH). Moreover, the role of lifestyle has not yet been comprehensively investigated.
Giulia Gilberti, Giorgio Tiecco, Silvia Marconi, Monica Marullo, Barbara Zanini, Eugenia Quiros‐Roldan   +5 more
wiley   +1 more source

Effects of enzyme inducers efavirenz and tipranavir/ritonavir on the pharmacokinetics of the HIV integrase inhibitor dolutegravir

European Journal of Clinical Pharmacology, 2014
PurposeDolutegravir (DTG) is an unboosted, integrase inhibitor for the treatment of HIV infection. Two studies evaluated the effects of efavirenz (EFV) and tipranavir/ritonavir (TPV/r) on DTG pharmacokinetics (PK) in healthy subjects.MethodsThe first ...
I. Song, J. Borland, Shuguang Chen, P. Guta, Y. Lou, D. Wilfret, T. Wajima, P. Savina, A. Peppercorn, S. Castellino, D. Wagner, L. Hosking, M. Mosteller, J. Rubio, S. Piscitelli   +14 more
semanticscholar   +1 more source

Dolutegravir Inhibits Autophagy In Vitro in a Mouse Blood–Brain Barrier Model

The FASEB Journal, Volume 39, Issue 12, 30 June 2025.
Antiretroviral drug dolutegravir inhibits autophagy function in the mouse brain microvascular endothelial cells. Created with BioRender. ABSTRACT Despite the effectiveness and tolerability of antiretroviral therapy (ART) in treating HIV infection, integrase strand transfer inhibitors, particularly dolutegravir (DTG)‐based ART, have been associated with
Chang Huang, Qing Rui Qu, Reina Bendayan
wiley   +1 more source